Third Androgel Trial Starts

[Jinzang]

The argument the lawyer is making is that AbbieVie failed to warn doctors that their testosterone gel increases the risk of thrombosis (blood clots). The news article says:

In opening arguments for the third bellwether trial against AbbVie in the multidistrict litigation over testosterone replacement therapy drugs, counsel for plaintiff Robert Nolte said the label on AndroGel only said doctors needed to monitor their patients’ red blood cell counts to protect them from a risk of blood clots.

But AbbVie knew that AndroGel could increase men’s risk of blood clots through other mechanisms, Nolte’s attorney, Ronald E. Johnson Jr. of Schachter Hendy & Johnson PSC, told the jury. The label didn’t mention those mechanisms, he said.

Nolte was already at risk of blood clots due to a medical condition, Johnson said. But based on AndroGel’s label, his doctor believed that if Nolte’s red blood cell count was monitored, he could safely take the drug.